Although the impacts of LAG-3-MHC-II interaction on CD4+ T cell immunity have been well studied, it was poorly understood as to how LAG-3 negatively regulates CD8+ T cell-mediated anti-tumor immunity [119, 120]. The gene discussed is CD8A; the disease is neoplasm.